Regencell Bioscience Announces 38-for-1 Stock Split

Ticker: RGC · Form: 6-K · Filed: 2025-06-02T00:00:00.000Z

Sentiment: neutral

Topics: stock-split, corporate-action

TL;DR

Regencell is doing a 38-for-1 stock split, giving shareholders 37 extra shares per share owned.

AI Summary

Regencell Bioscience Holdings Limited announced on June 2, 2025, that its board of directors approved a 38-for-one forward stock split, effective for shareholders of record on June 12, 2025. This means each shareholder will receive 37 additional shares for every share they own.

Why It Matters

A stock split can make shares more accessible to a wider range of investors by lowering the per-share price, potentially increasing liquidity.

Risk Assessment

Risk Level: low — This filing is a routine corporate action (stock split) and does not involve significant financial or operational changes.

Key Numbers

38-for-one — Stock Split Ratio (Indicates the number of new shares issued for each existing share.)
37 — Additional Shares per Share (The number of bonus shares shareholders will receive for each share held.)

Key Players & Entities

Regencell Bioscience Holdings Limited (company) — The company announcing the stock split.
June 12, 2025 (date) — Record date for the stock split.
38-for-one (stock_split_ratio) — The ratio of the forward stock split.

FAQ

What is the purpose of the 38-for-one forward stock split?

The filing does not explicitly state the purpose, but stock splits are often done to increase share liquidity and make the stock more accessible to investors.

Who is eligible to receive the additional shares?

Shareholders of record at the close of business on June 12, 2025, will receive the additional shares.

When is the record date for the stock split?

The record date is June 12, 2025.

What is the ratio of the stock split?

The stock split is a 38-for-one forward stock split, meaning shareholders will receive 37 additional shares for every one share they hold.

What type of filing is this?

This is a Form 6-K, which is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

From the Filing

0001213900-25-049674.txt : 20250602 0001213900-25-049674.hdr.sgml : 20250602 20250602062809 ACCESSION NUMBER: 0001213900-25-049674 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250602 FILED AS OF DATE: 20250602 DATE AS OF CHANGE: 20250602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Regencell Bioscience Holdings Ltd CENTRAL INDEX KEY: 0001829667 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: E9 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40617 FILM NUMBER: 251013070 BUSINESS ADDRESS: STREET 1: 11/F FIRST COMMERCIAL BUILDING STREET 2: 33-35 LEIGHTON ROAD, CAUSEWAY BAY CITY: HONG KONG STATE: K3 ZIP: 999077 BUSINESS PHONE: 852 2155 0823 MAIL ADDRESS: STREET 1: 11/F FIRST COMMERCIAL BUILDING STREET 2: 33-35 LEIGHTON ROAD, CAUSEWAY BAY CITY: HONG KONG STATE: K3 ZIP: 999077 6-K 1 ea0244186-6k_regencell.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-40617 Regencell Bioscience Holdings Limited (Registrant’s Name) 9/F Chinachem Leighton Plaza 29 Leighton Road Causeway Bay, Hong Kong (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Forward Stock Split The board of directors of Regencell Bioscience Holdings Limited (the “Company”) approved a 38-for-one forward stock split to be paid in the form of a stock bonus. Each shareholder of the Company of record at the close of business on June 12, 2025 will receive 37 additional shares for every share held on the record date. The Company expects the additional shares will be distributed on June 13, 2025. Subject to the final approval by the Nasdaq Capital Market, trading is expected to begin on a post-stock split adjusted basis at market open on June 16, 2025. Following the split, the Company’s outstanding shares will be increased at the ratio of the forward stock split. The Company’s authorized share capital and the share par value will remain unchanged. There will be no change to the Company’s name, CUSIP or its current trading symbol in connection with the forward stock split. No action is required by shareholders in connection with the forward stock split. Shareholders who hold their shares through a brokerage account will have their shares automatically adjusted to reflect the forward stock split. Registered shareholders will receive their additional shares through the Company’s transfer agent. Exhibit No. Description 99.1 Press Release, dated June 2, 2025 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: June 2, 2025 Regencell Bioscience Holdings Limited By: /s/ Yat-Gai Au Name: Yat-Gai Au Title: Chief Executive Officer and Chairman of the Board of Directors 2 EX-99.1 2 ea024418601ex99-1_regencell.htm PRESS RELEASE, DATED JUNE 2, 2025 Exhibit 99.1 Regencell Bioscience Holdings Limited Announces Forward Stock Split HONG KONG, June 2, 2025 – Regencell Bioscience Holdings Limited (Nasdaq: RGC) (the “Company”), today announced that its board of directors approved a 38-for-one forward stock split to be paid in the form of a stock bonus. Each shareholder of the Company of record at the close of business on June 12, 2025 will receive 37 additional shares for every share held on the record date. The Company expects the additional shares will be distributed on June 13, 2025. Subject to the final approval by the Nasdaq Capital Market, trading i